BMI is significantly related with the survival efficacy of ICI therapy in patients with NSCLC treated with second‐line or subsequent‐line PD‐1/PD‐L1 blockade therapy, and is reported to have better outcomes for patients with a high BMI. The gene discussed is CD274; the disease is non-small cell lung carcinoma.